{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:32:21Z","timestamp":1789435941257,"version":"build-2803163510"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"DOI":"10.7759\/cureus.98021","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:33:06Z","timestamp":1764351186000},"source":"Crossref","is-referenced-by-count":1,"title":["Bevacizumab-Associated Bowel Perforation Causing Evisceration"],"prefix":"10.7759","author":[{"given":"Maziar","family":"Fazel Darbandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garrett","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Vergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan E","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, et al.. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023, 72:338-44. 10.1136\/gutjnl-2022-327736","journal-title":"Gut"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihim\u00e4ki M","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016, 6:29765. 10.1038\/srep29765","journal-title":"Sci Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021702","article-title":"Current targeted therapy for metastatic colorectal cancer","volume":"24","author":"Ohishi T","year":"2023","unstructured":"Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M. Current targeted therapy for metastatic colorectal cancer. Int J Mol Sci. 2023, 24:24. 10.3390\/ijms24021702","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz H","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004, 350:2335-42. 10.1056\/NEJMoa032691","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2300385","article-title":"Combination therapy, including bevacizumab, for advanced colorectal cancer","volume":"388","author":"Yeku OO","year":"2023","unstructured":"Yeku OO, Longo DL. Combination therapy, including bevacizumab, for advanced colorectal cancer. N Engl J Med. 2023, 388:1711-4. 10.1056\/NEJMe2300385","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15\u00a0years of clinical experience and future outlook","volume":"86","author":"Garcia J","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15\u00a0years of clinical experience and future outlook. Cancer Treat Rev. 2020, 86:102017. 10.1016\/j.ctrv.2020.102017","journal-title":"Cancer Treat Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0190","article-title":"Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study","volume":"17","author":"Bendell JC","year":"2012","unstructured":"Bendell JC, Bekaii-Saab TS, Cohn AL, et al.. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012, 17:1486-95. 10.1634\/theoncologist.2012-0190","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-012-0426-4","article-title":"Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients","volume":"18","author":"Saito S","year":"2013","unstructured":"Saito S, Hayashi N, Sato N, et al.. Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients. Int J Clin Oncol. 2013, 18:689-95. 10.1007\/s10147-012-0426-4","journal-title":"Int J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular adverse events in patients with cancer treated with Bevacizumab: a meta-analysis of more than 20000 patients","volume":"6","author":"Totzeck M","year":"2017","unstructured":"Totzeck M, Mincu RI, Rassaf T. Cardiovascular adverse events in patients with cancer treated with Bevacizumab: a meta-analysis of more than 20000 patients. J Am Heart Assoc. 2017, 6:006278. 10.1161\/JAHA.117.006278","journal-title":"J Am Heart Assoc"},{"key":"ref10","article-title":"Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review","volume":"82","author":"Willems E","year":"2019","unstructured":"Willems E, Gerne L, George C, D'Hondt M. Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review. Acta Gastroenterol Belg. 2019, 82:322-5.","journal-title":"Acta Gastroenterol Belg"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2022.09.018","article-title":"Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: a nationwide database study","volume":"49","author":"Chen YH","year":"2023","unstructured":"Chen YH, Su YC, Hsu CW, et al.. Mortality of patients with metastatic colorectal cancer who received elective or emergent operation after exposure to bevacizumab: a nationwide database study. Eur J Surg Oncol. 2023, 49:445-51. 10.1016\/j.ejso.2022.09.018","journal-title":"Eur J Surg Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.11.009","article-title":"Clinical predictors of bevacizumab-associated gastrointestinal perforation","volume":"120","author":"Tanyi JL","year":"2011","unstructured":"Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, Chu CS. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol. 2011, 120:464-9. 10.1016\/j.ygyno.2010.11.009","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"32","author":"Burger RA","year":"2014","unstructured":"Burger RA, Brady MF, Bookman MA, et al.. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2014, 32:1210-7. 10.1200\/JCO.2013.53.6524","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1687-9","article-title":"Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups","volume":"70","author":"Qi WX","year":"2014","unstructured":"Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014, 70:893-906. 10.1007\/s00228-014-1687-9","journal-title":"Eur J Clin Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-008-9125-4","article-title":"Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation","volume":"26","author":"Tol J","year":"2008","unstructured":"Tol J, Cats A, Mol L, et al.. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008, 26:393-7. 10.1007\/s10637-008-9125-4","journal-title":"Invest New Drugs"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9337-9","article-title":"Gastrointestinal perforation due to bevacizumab in colorectal cancer","volume":"14","author":"Saif MW","year":"2007","unstructured":"Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol. 2007, 14:1860-9. 10.1245\/s10434-006-9337-9","journal-title":"Ann Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.12.004","article-title":"Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases","volume":"64","author":"Lordick F","year":"2006","unstructured":"Lordick F, Geinitz H, Theisen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006, 64:1295-8. 10.1016\/j.ijrobp.2005.12.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.gie.2011.06.008","article-title":"GI perforation associated with bevacizumab","volume":"75","author":"Yoon SS","year":"2012","unstructured":"Yoon SS, Rivera R, Shah A, Ozden N. GI perforation associated with bevacizumab. Gastrointest Endosc. 2012, 75:1286-7. 10.1016\/j.gie.2011.06.008","journal-title":"Gastrointest Endosc"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2019.00019","article-title":"Hernia and cancer: the points where the roads intersect","volume":"6","author":"Kulacoglu H","year":"2019","unstructured":"Kulacoglu H, K\u00f6ckerling F. Hernia and cancer: the points where the roads intersect. Front Surg. 2019, 6:19. 10.3389\/fsurg.2019.00019","journal-title":"Front Surg"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.4220","article-title":"Parastomal hernia","volume":"90","author":"Carne PW","year":"2003","unstructured":"Carne PW, Robertson GM, Frizelle FA. Parastomal hernia. Br J Surg. 2003, 90:784-93. 10.1002\/bjs.4220","journal-title":"Br J Surg"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-021-01288-y","article-title":"Risk factors for developing high-output ileostomy in CRC patients: a retrospective study","volume":"21","author":"Bai D","year":"2021","unstructured":"Bai D, Li L, Shen Z, et al.. Risk factors for developing high-output ileostomy in CRC patients: a retrospective study. BMC Surg. 2021, 21:300. 10.1186\/s12893-021-01288-y","journal-title":"BMC Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13017-017-0149-y","article-title":"2017 update of the WSES guidelines for emergency repair of complicated abdominal wall hernias","volume":"12","author":"Birindelli A","year":"2017","unstructured":"Birindelli A, Sartelli M, Di Saverio S, et al.. 2017 update of the WSES guidelines for emergency repair of complicated abdominal wall hernias. World J Emerg Surg. 2017, 12:37. 10.1186\/s13017-017-0149-y","journal-title":"World J Emerg Surg"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/431614-bevacizumab-associated-bowel-perforation-causing-evisceration","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T17:33:06Z","timestamp":1764351186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/431614-bevacizumab-associated-bowel-perforation-causing-evisceration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.98021","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}